INDICATIONS FOR ICD INSERTION

Ischemic Heart Disease (CAD)
(Al-Khatib 2017, Priori 2015, Russo 2013)

- Patients with documented ventricular fibrillation (VF), hemodynamically unstable ventricular tachycardia (VT), or sustained VT, after exclusion of reversible causes
- Syncope of undetermined origin, with one of the following:
  - Inducible VF or sustained VT at electrophysiological study (EPS), or
  - Left ventricular ejection fraction (LVEF) ≤ 35%
- LVEF ≤ 35% due to ischemic heart disease and NYHA class II or III, despite guideline-directed medical therapy (GDMT), and at least 40 days post myocardial infarction (MI) and 90 days post-revascularization
- LVEF ≤ 30% due to ischemic heart disease, NYHA class I, II, or III despite GDMT, and at least 40 days post-MI and 90 days post-revascularization (Al-Khatib 2017, Russo 2013)

Nonischemic cardiomyopathy (NICM)
(Al-Khatib 2017)

- Patients with documented VF, hemodynamically unstable VT, or sustained VT, after exclusion of reversible causes
- Syncope that is presumed to be due to ventricular arrhythmia
- NICM with LVEF ≤ 35% and NYHA functional Class II or III, despite at least 3 months of GDMT
- NICM due to a Lamin A/C gene mutation, who have ≥ 2 risk factors from the following (NSVT, LVEF < 45%, Male sex, nonmissense mutation)

Advanced Heart Failure & Transplantation
(Al-Khatib 2017, Priori 2015)

- In nonhospitalized patients with NYHA class IV who are candidates for cardiac transplantation or left ventricular assist device (LVAD) (Al-Khatib 2017, Priori 2015, Russo 2013)
- In a patient with an LVAD, sustained ventricular arrhythmias (Al-Khatib 2017)
- In NYHA ambulatory class IV, with appropriate indications for CRT (see Background Information section for definition of ambulatory NYHA class IV)
Myocardial Diseases

- **Hypertrophic cardiomyopathy** (HCM) with ≥ 1 major risk factors for SCD (Al-Khatib 2017, Epstein 2012, Gersh 2011, Shen 2017):
  - Prior sudden cardiac arrest (SCA) due to VT or VF
  - Documentation of sustained VT with syncope or hemodynamic compromise
  - Maximum LV wall thickness ≥ 30 mm
  - SCD in 1 or more first degree relatives
  - ≥ 1 episode of unexplained syncope within the preceding 6 months
  - Documented NSVT with an additional SCD risk modifier (age < 30 yr, delayed hyperenhancement on cardiac MRI, LVOT obstruction, or syncope > 5 yr ago) or high-risk feature (LV aneurysm or LVEF < 50%)
  - Abnormal BP response to exercise with an additional SCD risk modifier or high-risk feature (see above)
    - BP rise < 20 mmHg or fall of > 20 mmHg during exercise

- **Cardiac Sarcoidosis** with one of the following (Al-Khatib 2017, Priori 2015, Shen 2017):
  - Cardiac arrest or documented sustained VT
  - LVEF ≤ 35%
  - LVEF > 35% with inducible sustained ventricular arrhythmia at EPS
  - Syncope and/or scar on CMR or positron emission tomography (PET)
  - Requires a permanent pacemaker

- **Neuromuscular Disorders** with one of the following (Al-Khatib 2017):
  - Primary and secondary prevention, with same indications as for NICM (Priori 2016)
  - Emery-Dreifuss or limb-girdle type I-B muscular dystrophy with progressive cardiac involvement

- **Arrhythmogenic right ventricular cardiomyopathy** and ≥ 1 of the following risk factors for SCD:
  - Resuscitated sudden cardiac arrest
  - Sustained VT
  - Right or left ventricular systolic dysfunction with an ejection fraction ≤ 35%
  - Syncope with documented or presumed ventricular arrhythmia

Channelopathies

- **Congenital long QT syndrome** with one of the following (Al-Khatib 2017, Epstein 2012, Goldenberg 2008, Priori 2015, Schwartz 2012)
  - Sudden cardiac arrest
  - Sustained VT or recurrent syncope when beta blocker is ineffective or not tolerated
  - QTc > 500 ms on a beta blocker (Al-Khatib 2017)
  - Strong family history of SCD
  - High risk genotype (type 2 and type 3)

- **Brugada syndrome and spontaneous type 1 Brugada electocardiographic pattern** with one of the following:
  o Cardiac arrest
  o Documented sustained ventricular arrhythmia
  o Syncope due to ventricular arrhythmia

• Catecholaminergic polymorphic VT with one of the following (Al-Khatib 2017, Priori 2013, Epstein 2012, Russo 2013):
  o Sudden cardiac arrest
  o Syncope or sustained VT
  o Inducible VT or VF

• Early Repolarization or Short QT Syndrome with one of the following (Al-Khatib 2017, Priori 2015):
  o Cardiac arrest
  o Sustained ventricular arrhythmia

• Idiopathic Polymorphic VT/VF with one of the following (Al-Khatib 2017):
  o Cardiac arrest due to polymorphic VT or VF

Miscellaneous

Adult & Pediatric Congenital (Structural) Heart Disease (ACHD)

• Cardiac arrest due to VF or VT after exclusion of a reversible etiology

• Systemic LVEF ≤ 35%, biventricular physiology, and NYHA class II or III on GDMT.

• Tetralogy of Fallot with one of the following (Al-Khatib 2017, Shen 2017):
  o Spontaneous sustained VT
  o Inducible VF or sustained VT
  o ≥ 1 risk from the following list:
    ▪ Prior palliative systemic to pulmonary shunts
    ▪ Unexplained syncope
    ▪ Frequent PVCs
    ▪ Atrial tachycardia
    ▪ Left ventricular dysfunction or diastolic dysfunction
    ▪ NSVT
    ▪ QRS duration ≥ 180 ms
    ▪ Dilated right ventricle
    ▪ Severe pulmonary regurgitation or stenosis

• Single or systemic right ventricular ejection fraction (RVEF) < 35%, in the presence of an additional risk factor such as:
  o NSVT
  o Unexplained syncope
- NYHA class II or III, despite GDMT (Al-Khatib 2017, Priori 2015)
- QRS duration ≥ 140 ms
- Severe systemic AV valve regurgitation

- Syncope of unknown origin in the presence of either advanced ventricular dysfunction (EF < 35%) or marked hypertrophy or inducible sustained VT or VF (Al-Khatib 2017, Shen 2017)

- Syncope and moderate or complex congenital heart disease (CHD), with high clinical suspicion of ventricular arrhythmias

- Non-hospitalized patients with CHD awaiting heart transplantation

- Left ventricular non-compaction that meets same indications as NICM, including a familial history of SCD (Biagini 2006, Russo 2018)

**EXEMPTIONS:**

*Indications for ICD with an Appropriate Pacing Modality in Special Situations* (Katsumoto 2014, Russo 2013)*

- ICD criteria met, and elevated troponin is deemed not due to a myocardial infarction (Al-Khatib 2017)

- ICD criteria met, except for myocardial infarction within 40 days or revascularization within 3 months, but a non-elective permanent pacemaker (new or replacement) is required, and recovery of left ventricular function to LVEF > 35% is uncertain or not expected (Russo 2013)**

- ICD criteria met, except NICM or ischemic cardiomyopathy has not had 3 months’ time for LVEF to improve on medical therapy, a non-elective permanent pacemaker is required, and recovery of LVEF is uncertain or not expected**

- Patient met primary prevention criteria for an ICD prior to coronary revascularization, and it is unlikely that LVEF will recover to > 35% despite a 90 day wait (Katsumoto 2014)

* With these ICD indications, CRT would sometimes be the appropriate pacing modality. CRT is highly likely to be the appropriate modality when > 40% rhythm requires pacing.

** These indications avoid a second implantation procedure within less than 3 months.

**BACKGROUND:**


The implantable cardioverter defibrillator (ICD) has become valuable in the management of patients with ventricular arrhythmias (VA) capable of causing syncope, cardiac arrest, and sudden cardiac death (SCD).

Patient eligibility for an ICD presumes all of the following:

- Anticipated reasonable quality of life for ≥ 1 year post implantation (Katsumoto 2018)
- Patient’s ability to live with a shock-delivering device that requires management
- Absence of a *completely* reversible cause that led to VA for which an ICD is being considered (see Background Information section on reversible causes)
- Completion of $\geq 3$ months of guideline directed medical therapy (GDMT) for heart failure (HF), unless an intervening indication for pacemaker implantation arises (see Background Information section for definition of GDMT)
- ICD indications are present in the vast majority of scenarios in which cardiac resynchronization therapy (CRT) is appropriate
- Sustained VT is defined as having duration $> 30$ seconds or requiring termination due to hemodynamic compromise in $< 30$ seconds

Guidelines for the pediatric population are extrapolated from the adult population, due to a lack of relevant trials (Brugada 2013, Priori 2015)

**OVERVIEW:**

**General**


Implantable cardioverter defibrillators (ICDs) are indicated for the treatment of life-threatening ventricular tachycardia and ventricular fibrillation. An ICD system includes a pulse generator and one or more leads. ICDs are indicated both for patients who have survived life-threatening rhythm disturbances (secondary prevention) and for those who are at risk for them (primary prevention)

- An ICD continually monitors heart rhythm. If a rapid rhythm is detected, the device delivers electrical therapy directly to the heart muscle in order to terminate the rapid rhythm and restore a normal heart rhythm. There are two types of therapy that can be delivered:
  - Rapid pacing
  - High-voltage shocks are necessary for ventricular fibrillation and also for instances where rapid pacing has failed to correct the abnormal rhythm
- In addition, all ICDs have pacing capability, and they deliver pacing therapy for slow heart rhythms (bradycardia)
- The parameters defining limits for pacing therapy and for tachycardia therapy are programmable using noninvasive radio signals on all available ICDs

**Waiting Period** is an important issue in ICD insertion for primary prevention. This has resulted from guidelines and payment policies which mirror the inclusion criteria of primary and secondary prevention trials (Dukkipati 2017a, Dukkipati 2017b).

**NYHA Class Definitions**

(Campeau 1976, Goldman 1981, Russo 2013)

- **Class I:** No limitation of functional activity or only at levels of exertion that would limit normal individuals (patient can carry 24 pounds up 8 stairs, play basketball, and shovel soil).
- **Class II**: Slight limitation of activity. Fatigue, palpitation, or dyspnea with moderate exercise (patient able to dance, garden, and walk 4 MPH on level ground).
- **Class III**: Marked limitation of activity. Fatigue, palpitation, or dyspnea with minimal activity (patient able to shower, make bed, bowl or golf, dress, and walk 2.5 MPH on level ground).
- **Class IV**: Severe limitation of activity. Symptoms even at rest, worse with activity (patient unable to comfortably perform any significant activity).
- **Ambulatory Class IV**: Class IV heart failure with: 1) no active acute coronary syndrome; 2) no inotropes; and 3) on GDMT.

**Guideline Directed (or Optimal) Medical Therapy for Heart Failure**
(Yancy 2013, Yancy 2017)

- Angiotensin converting enzyme (ACE-I), angiotensin receptor blockers (ARB), or combined angiotensin receptor inhibitor and neprilysin inhibitor (ARNI)
- Beta blocker (might be less critical in permanent atrial fibrillation, still recommended) (Kotecha 2017)
- Addition of loop diuretic for all NYHA class II – IV patients
- Addition of hydralazine and nitrate for persistently symptomatic African Americans
- Addition of an aldosterone antagonist, provided eGFR is > 30 ml/mi
- Normal serum sodium and potassium
- Not required for consideration of ICD: Ivabradine for NYHA class II – III, when a beta blocker has failed to reduce a sinus rate to < 70 bpm. Ivabradine listed as a class IIa recommendation, while others are class I recommendations. CRT trials antedated routine use of Ivabradine.
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE-I</td>
<td>Angiotensin converting enzyme inhibitor</td>
</tr>
<tr>
<td>ACHD</td>
<td>Adult congenital heart disease</td>
</tr>
<tr>
<td>ARNI</td>
<td>Combined angiotensin receptor inhibitor and neprilysin inhibitor</td>
</tr>
<tr>
<td>ARVD/C</td>
<td>Arrhythmogenic right ventricular dysplasia/cardiomyopathy</td>
</tr>
<tr>
<td>AV</td>
<td>Atrioventricular</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary artery disease, same as ischemic heart disease</td>
</tr>
<tr>
<td>CHD</td>
<td>Congenital heart disease</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CRT-D</td>
<td>Cardiac resynchronization therapy ICD system</td>
</tr>
<tr>
<td>DCM</td>
<td>Dilated cardiomyopathy</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>EPS</td>
<td>Electrophysiologic Study</td>
</tr>
<tr>
<td>GDMT</td>
<td>Guideline-Directed Medical Therapy</td>
</tr>
<tr>
<td>HCM</td>
<td>Hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HRS</td>
<td>Heart Rhythm Society</td>
</tr>
<tr>
<td>HV</td>
<td>His-ventricle</td>
</tr>
<tr>
<td>ICD</td>
<td>Implantable cardioverter-defibrillator</td>
</tr>
<tr>
<td>LBBB</td>
<td>Left bundle-branch block</td>
</tr>
<tr>
<td>LV</td>
<td>Left ventricular/left ventricle</td>
</tr>
<tr>
<td>LVAD</td>
<td>Left ventricular assist device, mechanical heart</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>ms</td>
<td>Milliseconds</td>
</tr>
<tr>
<td>NICM</td>
<td>Nonischemic cardiomyopathy</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
<tr>
<td>RV</td>
<td>Right ventricular/right ventricle</td>
</tr>
<tr>
<td>STEMI</td>
<td>ST-elevation myocardial infarction</td>
</tr>
<tr>
<td>SND</td>
<td>Sinus node dysfunction</td>
</tr>
<tr>
<td>VT</td>
<td>Ventricular tachycardia</td>
</tr>
<tr>
<td>VF</td>
<td>Ventricular fibrillation</td>
</tr>
</tbody>
</table>
POLICY HISTORY:
Review Date: August 14, 2019
Review Summary:

- Removed indications under ischemic heart disease for NSVT due to prior MI, LVEF ≤ 40%, and inducible VT or VF at EPS
- Removed indications under ischemic heart disease for VT or VF < 48 hours post MI or elective coronary revascularization
- Under NICM, removed indication for peripartum cardiomyopathy with LVEF ≤ 35% that persists > 3 months
- Under advanced heart failure and transplantation, removed indication for severe allograft vasculopathy
- Revision to cardiac sarcoidosis indication to add cardiac arrest
- Under hypertrophic cardiomyopathy revised indications for documented NSVT to include an additional SCD risk modifier (age < 30 yr, delayed hyperenhancement on cardiac MRI, LVOT obstruction, or syncope > 5 yr ago) or high risk feature (LV aneurysm or LVEF < 50%)
- Removed indications for giant cell myocarditis and chronic Chagas cardiomyopathy
- Removed indication for hypertensive heart disease with LVH and LVEF ≤ 35%
- Under Tetrology of Fallot added the following indications:
  - Prior palliative systemic to pulmonary shunts
  - Unexplained syncope
  - Frequent PVCs
  - Atrial tachycardia
  - Left ventricular diastolic dysfunction
  - Dilated right ventricle
REFERENCES:


Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for


Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. *Circulation*. 2011; 124:2181-2184. Available at: http://circ.ahajournals.org/content/124/20/2181


Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.